Onctura has dosed the first subject in the open-label Phase II OCULE-01 trial of oral roginolisib in individuals with rare ...

The summer of 2023 saw the approval of a new treatment option for certain patients with uveal melanoma, a form of cancer that begins in the eye and remains a challenge to treat. Richard Staines ...

As many as half of people diagnosed with uveal melanoma (ocular melanoma) go on to have what’s called metastatic disease. Most often, the cancer metastasizes (spreads) beyond the eye to the ...

There’s a rare form of eye cancer which may not give you any symptoms, but can be extremely serious if developed. Uveal melanoma, a rare form of eye cancer, affects between 500 and 600 people in ...

Mayo Clinic researchers have developed organoid models to study uveal melanoma, one of the most common types of eye cancer in adults. Their goal is to use these models to better understand how ...

Uveitis is a serious and sometimes painful eye condition that shouldn't be ignored. It's caused by inflammation in the uvea, a layer of tissue just inside the outer white part of your eye.

First patient dosed in Phase II OCULE-01 study with roginolisib, an allosteric modulator of PI3Kδ <li /> The European Medicines Agency (E ...

It is the first treatment of its kind for mUM, a cancer that develops from cells in the middle layer of the eye, known as the uvea. It is very uncommon – affecting a few thousand people across ...

including a doubling of overall survival compared to historical controls in rare eye cancer, uveal melanoma. The company has carefully designed its clinical program to allow full development in ...

L V Prasad Eye Institute highlights eye cancer is rare but serious threat that needs more awareness. Most people associate cancer with the lungs, breast, or skin, but few realize that cancer can also ...

Uveal melanoma a common eye cancer in the West. It is relatively rare in India. Depending on the type of tumour, eye cancers may develop due to various risk factors, including genetic and familial ...